至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Complement factor C4a does not activate protease activated receptor 1 (PAR1) or PAR4 on human platelets

Research and Practice in Thrombosis and Haemostasis. 2026-03; 
Xu Han; Maria de la Fuente; Marvin T. Nieman
Products/Services Used Details Operation
Peptide Synthesis PAR1 activation peptide, SFLLRN NH 2 and TFLLRN NH 2 were from Tocris Bioscience (Minneapolis, MN, USA). PAR4 activation peptide, AYPGKF NH 2 , was from GenScript (Piscataway, NJ, USA). C4a (catalog no. A106, Lot 16) was from Complement Technology (Tyler, TX, USA). Human thrombin (catalog # HCT 0020, specific Get A Quote

摘要

AbstractBackground Protease activated receptor (PAR) 1 and PAR4 are key thrombin signal mediators for human platelet activation and aggregation in response to vascular injury. They are primarily activated by thrombin cleavage of the N terminus to expose a tethered ligand. In addition to the canonical activation by thrombin, a growing panel of proteases can also elicit PAR1 or PAR4 mediated signal transduction. Recently, complement factor C4a was reported as the first endogenous agonist for both PAR1 and PAR4. Further, it is the first endogenous nontethered ligand that activates PAR1 and PAR4. These studies were conducted with human microvascular cells; the impact of C4a on platelet PARs is unknown.Objectives Th... More

关键词

complement factor C4a, PAR1, PAR4, platelet aggregation, platelets